Stock chart
Analyses on Biolight (4)
- March 15, 2026March 15, 2026
- Follow-up
Biolight 2025: How Much of the Portfolio Value Is Actually Accessible to Shareholders?
At Biolight the question is not only how much the portfolio is worth on the books, but how much of it can realistically turn into shareholder-accessible value. At year-end 2025 most of that value still depends on level-3 marks, a SAFE that has not yet converted, or very early co…
- Follow-up
Biolight 2025: Can OCUVIA Move from Development Platform to a Real Value Event?
OCUVIA is Biolight's most advanced attempt to turn several early ophthalmology programs into one capital-markets story, but for now it is still a platform that runs ahead of the value event: management exists, the US financing or listing ambition exists, and the underlying data…
- Follow-up
Biolight 2025: How Long Does the Parent Cash Box Really Last, and When Does Dilution Return?
Biolight's parent cash box is real and sufficient for the near term, but it buys time rather than removes dilution: once the market concludes that the portfolio will not generate a financing or commercialization event before the 24-month window starts to shorten, the capital que…
Biolight 2025: The Raise Bought Time, But Value Still Needs Proof
Biolight bought time and flexibility in 2025 through the public raise, but the next step in shareholder value will come only if the portfolio moves from scientific or regulatory proof to financing, partnership or commercialization proof.
